Proshares UltraPro NASDAQ Biotechnology
UBIO
UBIO was delisted on the 27th of March, 2020.
2 hedge funds and large institutions have $6K invested in Proshares UltraPro NASDAQ Biotechnology in 2015 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.7K |
| 2 |
Morgan Stanley
New York
|
+$1.57K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
1
Tower Research Capital (TRC)
New York
| $4K | +$3.7K | +40 | New |
|
|
2
Morgan Stanley
New York
| $2K | +$1.57K | +17 | New |
|
UBIO Hedge Fund Activity: Q2 2015 in Review
2 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in Proshares UltraPro NASDAQ Biotechnology (UBIO) for Q2 2015, worth a combined $6K.
Buyers outnumbered sellers: 2 funds opened new UBIO positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $3.7K.
- 2 institutional investors held Proshares UltraPro NASDAQ Biotechnology (UBIO) as of Q2 2015, up from 0 in Q1 2015.
- Funds reported $6K of Proshares UltraPro NASDAQ Biotechnology stock for Q2 2015.
- 2 funds opened new Proshares UltraPro NASDAQ Biotechnology positions in Q2 2015 and 0 closed out, a net change of +2 holders.
- The largest Proshares UltraPro NASDAQ Biotechnology buyer in Q2 2015 was Tower Research Capital (TRC), an estimated $3.7K added.
Based on aggregated 13F filings for Q2 2015.